Chemed Corporation (NYSE:CHE – Get Free Report) CEO Kevin Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $541.16, for a total value of $1,082,320.00. Following the sale, the chief executive officer owned 70,418 shares in the company, valued at $38,107,404.88. The trade was a 2.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Chemed Stock Performance
Shares of CHE stock traded up $0.92 during trading hours on Monday, reaching $541.49. The stock had a trading volume of 21,011 shares, compared to its average volume of 215,475. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $557.00. The firm has a 50-day simple moving average of $499.24 and a 200-day simple moving average of $446.50. The firm has a market capitalization of $7.08 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 2.05 and a beta of 0.51.
Chemed (NYSE:CHE – Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. During the same period in the previous year, the business posted $4.27 EPS. Chemed’s revenue was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, equities analysts forecast that Chemed Corporation will post 23.18 earnings per share for the current year.
Chemed Increases Dividend
Hedge Funds Weigh In On Chemed
Institutional investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. boosted its holdings in Chemed by 330.4% during the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Chemed by 67.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock valued at $5,534,000 after acquiring an additional 4,560 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Chemed in the 2nd quarter worth approximately $579,000. Brown Advisory Inc. grew its position in Chemed by 36.9% during the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock worth $267,000 after acquiring an additional 148 shares during the last quarter. Finally, Cerity Partners LLC increased its holdings in Chemed by 237.7% during the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock valued at $2,165,000 after purchasing an additional 3,133 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
CHE has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Chemed from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Oppenheimer lifted their price target on Chemed from $500.00 to $590.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Royal Bank Of Canada lifted their price objective on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th. Bank of America restated a “neutral” rating on shares of Chemed in a report on Wednesday, July 29th. Finally, Weiss Ratings raised Chemed from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $530.75.
Get Our Latest Stock Report on Chemed
Chemed Company Profile
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Recommended Stories
- Five stocks we like better than Chemed
- If Boeing Ramps Up Production, These Suppliers May Win Big
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
- 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here’s Why
- Aehr Test Systems Soars Again on Latest Orders, Jefferies Eyes Big-Time Upside Ahead
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
